Abstract 6073
Background
Thyroid carcinomas are fairly uncommon tumors. They include disease types that range from indolent behavior such as papillary carcinomas to the fulminant and lethal anaplastic disease. The aim of this study was to analyze the characteristics of patients diagnosed with thyroid carcinoma in the United States between 2000 till 2016.
Methods
This study was conducted using SEER*Stat version 8.3.5 to analyze clinical and pathological characteristics of thyroid carcinoma patients diagnosed in the period between 2000 and 2016 in the United States through exploiting the data obtained from SEER Regs Research Data Nov 2018. The data were statistically analyzed using SPSS version 20.
Results
A total of 172525 cases of thyroid carcinoma were diagnosed. The median age at diagnosis was 50 years. Females were the most common gender affected (n = 131059; 75.7%). The incidence rate of thyroid carcinoma was estimated to be 12 per 100,000 cases. Papillary adenocarcinoma, NOS was the most common histology (n = 84323; 48.7%), followed by follicular variant of papillary carcinoma (n = 46830, 27.1%). The disease was the only primary tumor in most of cases (n = 139831; 80.8%). The majority of patients had localized early disease at the time of diagnosis (Stage I = 89235; 51.5%), and surgery was performed in the vast majority of case (n = 164742; 95.2%). The median survival wasn’t reached, with observed survival, at 5 and 10 years, was 94.2% & 89.2% respectively and relative survival at 5 and 10 years was 98% & 97.4%, respectively.
Conclusions
Thyroid carcinoma is a disease of middle ages, mainly, with female predominance. Papillary thyroid carcinoma is the most common histology and most of patients tend to present at early stage. The survival is good with median survival wasn’t reached and relative 5- year and 10- year survival of 98% & 97.4%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract